Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2025 value amounting to $6000.0.

  • Ernexa Therapeutics' Tax Provisions fell 5000.0% to $6000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $28000.0, marking a year-over-year increase of 8666.67%. This contributed to the annual value of $30000.0 for FY2024, which is 110000.0% up from last year.
  • Per Ernexa Therapeutics' latest filing, its Tax Provisions stood at $6000.0 for Q3 2025, which was down 5000.0% from $3000.0 recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Tax Provisions peaked at $40000.0 during Q4 2022, and registered a low of -$8000.0 during Q3 2023.
  • Over the past 4 years, Ernexa Therapeutics' median Tax Provisions value was $5000.0 (recorded in 2022), while the average stood at $6846.2.
  • Its Tax Provisions has fluctuated over the past 5 years, first plummeted by 26000.0% in 2023, then surged by 37500.0% in 2024.
  • Ernexa Therapeutics' Tax Provisions (Quarter) stood at $40000.0 in 2022, then plummeted by 110.0% to -$4000.0 in 2023, then skyrocketed by 375.0% to $11000.0 in 2024, then crashed by 45.45% to $6000.0 in 2025.
  • Its Tax Provisions was $6000.0 in Q3 2025, compared to $3000.0 in Q2 2025 and $8000.0 in Q1 2025.